Romidepsin Overcomes Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma Cells

@article{Sripayap2013RomidepsinOC,
  title={Romidepsin Overcomes Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma Cells},
  author={Piyanuch Sripayap and Tadashi Nagai and Kaoru Hatano and Jiro Kikuchi and Yusuke Furukawa and Keiya Ozawa},
  journal={Acta Haematologica},
  year={2013},
  volume={132},
  pages={1 - 4}
}
5] . These effects might ultimately affect the expression and function of various intracellular molecules, including transcription factors. We therefore hypothesized that these agents influence the expression levels of adhesion molecules in MM cells. To verify this hypothesis, we examined the effect of the HDI romidepsin and DNAmethylating agent azacitidine on the expression levels of CD49d and two other representative adhesion molecules, CD29 and CD138, by flow cytometry analyses in two human… 

Figures from this paper

Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma
TLDR
These findings provide a rationale for the inclusion of epigenetic drugs, such as HDAC inhibitors and histone methylation modifiers, in combination chemotherapy for MM patients to increase the therapeutic index.
Phosphorylation-mediated EZH 2 inactivation promotes drug resistance in multiple myeloma
TLDR
The findings identify and characterize an epigenetic mechanism that underlies CAM-DR and suggest that kinase inhibitors to counteract EZH2 phosphorylation should be included in combination chemotherapy to increase therapeutic index.
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.
TLDR
The findings identify and characterize an epigenetic mechanism that underlies CAM-DR and suggest that kinase inhibitors to counteract EZH2 phosphorylation should be included in combination chemotherapy to increase therapeutic index.
Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells
TLDR
MiR-101-3p-survivin interaction is identified as a druggable target involved in stroma-mediated drug resistance in MM and suggests it for developing more efficient therapeutic strategies.
The Warburg effect in Multiple Myeloma and its microenvironment
TLDR
The stabilization and transcription of hypoxia-inducible factor 1 α under tumor-attributed hypoxic conditions shows promising downstream mechanisms such as histone deacetylase (HDAC), which can be targeted and serve as adjuvant therapy to prolong overall survival of MM patients.
Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells
TLDR
Bortezomib-induced up-regulation of CHOP was readily enhanced by lenalidomide in contact with stromal cells, and caspase-3 was activated more strongly by melphalan than by other agents in combination with bortzomib.
Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors.
Epigenetic Crosstalk between Malignant Plasma Cells and the Tumour Microenvironment in Multiple Myeloma
TLDR
This review discusses the crosstalk between the tumour microenvironment’s epigenetic mechanisms, the progression of multiple myeloma, and the onset of multipleMyeloma complications, such as bone disease.

References

SHOWING 1-10 OF 13 REFERENCES
Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma
TLDR
Functional screening using short hairpin RNA suggests that VLA-4 plays a critical role in CAM-DR of MM cells, and the combination of bortezomib with conventional anti-myeloma drugs may be effective in overcoming CAM- DR of MM.
Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.
TLDR
It is shown that histone deacetylases (HDACs) are critical targets of bortezomib, which specifically down-regulated the expression of class I HDACs in MM cell lines and primary MM cells at the transcriptional level, accompanied by reciprocal histone hyperacetylation.
Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.
TLDR
It is demonstrated that FN-mediated adhesion confers a survival advantage for myeloma cells acutely exposed to cytotoxic drugs by inhibiting drug-induced apoptosis, which may explain how some cells survive initial drug exposure and eventually express classical mechanisms of drug resistance such as MDR1 overexpression.
The Wilms Tumor Suppressor Wt1 Promotes Cell Adhesion through Transcriptional Activation of the α4integrin Gene*
TLDR
It is shown here that the Wilms tumor suppressor Wt1, which is necessary for normal development of the epicardium, coronary vessels, genitourinary system, and other tissues, activates transcription of the α4integrin gene.
Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors
TLDR
Sequential exposure to bortezomib in conjunction with clinically relevant HDAC inhibitors potently induces mitochondrial dysfunction and apoptosis in human MM cells through a ROS-dependent mechanism, suggesting that a strategy combining these agents warrants further investigation in MM.
Perspectives in the treatment of multiple myeloma
TLDR
The use of three to four drug combination therapies including PI and IMiDs has significantly impacted on MM patient outcome and molecular subgroup-specific trials using targeted agents may represent a very important step toward evaluating impact of interfering with relevant signaling pathways in MM.
5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy
TLDR
The current status of the understanding of the mechanism(s) by which 5-azacytosine residues in DNA inhibit DNA methylation is reviewed with an emphasis on the interactions of these residues with bacterial and mammalian DNA (cytosines-C5) methyltransferases.
Histone deacetylase inhibitors: Potential in cancer therapy
The role of histone deacetylases (HDAC) and the potential of these enzymes as therapeutic targets for cancer, neurodegenerative diseases and a number of other disorders is an area of rapidly
...
...